Ohio College of Clinical Pharmacy
Abstract Guidelines
Fall Meeting – Friday, November 13, 2015
Cleveland Airport Marriott
4277 West 150th Street · Cleveland, Ohio 44135
Abstract Construction
1. Submit abstracts using the template on the following page. Abstracts must be typed in
Microsoft Word. Abstracts must be typed in Arial size 10 font and must fit on a single 8.5 x 11
inch page of paper with 1 inch margins.
2. Abstracts should include the following information: title, authors names, degrees,
institution(s) where work was performed, PGY-X & specialty if applicable, contact email for
the first author (trainee), structured abstract (see template and example provided), and 3-5
references. Please do not use EndNote to prepare the reference section of the abstract.
3. All abstracts will be posted, as submitted, to the OCCP website (www.occpweb.org) on or
before the week of the meeting for downloading by attendees.
4. All file names should be in the following format: Last name_First Name
Poster Display
1. Posters should fit on a 4 ft. x 6 ft. cork board. Please bring your own push pins or tacks.
2. Poster boards will be available at the time of meeting registration. There will be two poster
sessions. You will be assigned to one of the sessions. Setup and teardown times are to be
determined.
3. Poster presenters should be available during their assigned poster session in order to
address any questions.
4. It will be the responsibility of the presenter to remove the poster at the end of the poster
session period.
Abstract Submission Due Date
1. The due date for abstract submission for this year’s program is Friday, October 9, 2015.
Abstracts should be submitted via the OCCP website (occpweb.org). If you have any
problems with uploading the abstracts through the website, please email Alia Poore at
alia.daghstani@gmail.com.
Meeting Registration
1. Please note that all poster presenters must register for the meeting and pay the registration
fee. Early registration is encouraged.
Title
Full names of authors and degrees (resident’s name bolded and listed first)
Contact information: (residents email address)
PGY-___
Specialty: (if applicable)
Research site/ Institution:
Background:
Objective:
Methodology:
Results and conclusions:
References:
(Please review the example abstract on the following page.)
Impact of Pharmacist Management of Dyslipidemia in Patients with Type 2
Diabetes Mellitus
Sarah Milkovich, PharmD, RPh; Nathan Stuckey, PharmD, BCPS, RPh; Lori Rose, PharmD, BCPS,
RPh; Courtney Pearson, MD; Carl Tyler, MD; James Bena, MS.
Resident’s email address: milkovs@ccf.org PGY-1 Pharmacy Practice Resident
Research Site: Cleveland Clinic – Fairview Hospital, 18101 Lorain Road Cleveland, OH 44111
Background: Diabetes is a chronic disease affecting approximately 25.8 million Americans. Diabetes
leads to many complications including cardiovascular disease. According to the 2013 ACC/AHA Update
on the Treatment of Blood Cholesterol in Adults, statin therapy is preferred to reduce the risk of
atherosclerotic cardiovascular disease (ASCVD) in diabetic patients.1 Several studies demonstrated the
positive impact of pharmacist intervention to decrease cardiovascular risk using previous NCEP/ATPIII
guidelines.2-5 To date, studies evaluating pharmacist managed dyslipidemia using current guidelines have
not been published.
Objectives: The primary objective of this study is to evaluate the change in the number of type 2
diabetes mellitus patients with appropriate statin therapy after pharmacist management of dyslipidemia
according to the 2013 ACC/AHA Treatment Guidelines.
Methodology: This study was completed at Fairview Hospital Center for Family Medicine, an established
pharmacist managed ambulatory care clinic with collaborative practice agreements. Diabetic patients age
21 years and older and referred to the program by a physician were enrolled in the study. Patients were
excluded if contraindications to statin therapy were documented. The initial standardized pharmacy
appointment included a comprehensive medication review, baseline lipid panel, drug therapy initiation or
modification, and education. The pharmacist contacted patients via telephone within two weeks if therapy
was initiated or medication changes occurred. Patients returned for a follow up visit approximately 12
weeks later to assess changes in lipid panel, medication adherence, and adverse effects. Patients in the
pharmacist intervention group were compared to patients receiving usual care by a physician, and
differences were assessed. Patients in both groups were matched according to age, gender,
intervention, and if two lipid panels were completed within a 12-month period.
Results and Conclusions: A total of 142 patients were eligible for the service, and 88 patients were
referred to the dyslipidemia service. Twenty-seven patients completed the initial pharmacy appointment,
and 9 patients completed the 12-week follow up appointment. After pharmacist intervention, more
patients were taking appropriate statin therapy compared to usual care (p=0.29). There was a significant
change in total and LDL cholesterol from baseline to follow up in pharmacist intervention patients
compared to usual care (p=0.012 and p=0.015). Initiation and optimization of statin therapy improves
adherence to guidelines in a short time frame, and frequent follow up by a pharmacist contributes to
greater total and LDL cholesterol reduction.
References:
1. Goff DC, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Circulation
Epub 12 November 2013.
2. Smith MC, et al. Effectiveness of a pharmacy care management program for veterans with
dyslipidemia. Pharmacotherapy 2013; 33(7): 736-743.
3. Cripps RJ, et al. An evaluation of diabetes-related measures of control after 6 months of clinical
pharmacy specialist intervention. Journal of Pharmacy Practice 2011(24): 332.
4. Ip EJ, et al. Enhancing diabetes care by adding a pharmacist to the primary care team. AJHP
2013; 70:877-86.
5. Sease JM, et al. Pharmacist management of patients with diabetes mellitus enrolled in a rural
free clinic. AJHP 2013; 70:43-7.